The slip
PARKINSON RECEIPTno. 7282
23 Oct 2026, 06:47 UTCdopamine neurons, braak
predictionZNF395 in dopamine neurons tracks Braak Lewy-body stage
registered260de25d17586b0c
discovery+0.34 p=0.373 n=9
replication+0.12 p=0.756 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.34, p 0.373)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT38cbbcdfa5426c8a232fb4df…
follows 44d63ce47b57…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 7282: ZNF395 in dopamine neurons, braak
- power
- full sample +0.20 (p 0.424, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.429, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.615, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.33, sign flips 0; without severely affected donors +0.20 (p 0.424, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0067, n 18) vs +0.20 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZNF395 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZNF395 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 2.9e-4)